Actively Recruiting
Butyrophilins Role in Colon Cancer
Led by Institut Paoli-Calmettes · Updated on 2025-06-15
200
Participants Needed
1
Research Sites
413 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
quantification of BTNL molecules in colon cancer in order to determinate if their could be used as a prognostic marquer
CONDITIONS
Official Title
Butyrophilins Role in Colon Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient is older than 18 years old
- Signed participation consent
- Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous planned for combined colon and liver surgery
- Performance Status (PS) 0 or 1
- Affiliated to social security or beneficiary
You will not qualify if you...
- Rectal cancer or colon cancer recurrence
- Emergency colon cancer surgery
- History of inflammatory bowel disease (Crohn's disease or ulcerative colitis)
- Received neoadjuvant therapy other than chemotherapy
- Treated with immune suppressors or long-course corticosteroids in the last 12 months
- Pregnant, likely to be pregnant without effective contraception, or breastfeeding
- Person in urgent situation, under legal protection, or unable to give consent
- Unable to undergo medical examination due to geographical, social, or psychological reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut Paoli-Calmettes
Marseille, France, 13273
Actively Recruiting
Research Team
J
Jihane PAKRADOUNI, PharmD,PhD
CONTACT
L
Laurie-Anne GOUTY, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here